NPS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs and recombinant proteins. The Company’s portfolio of approved drugs and product candidates are primarily for the treatment of bone and mineral disorders, gastrointestinal disorders and central nervous system disorders. Its product portfolio consists of one United States Food and Drug Administration (FDA) approved product, another product candidate that has been granted marketing approval in Europe, and is the subject of an approvable letter from the FDA in response to a new drug application NPS Pharmaceuticals, Inc. filed in May 2005, a product candidate that is the subject of a pivotal Phase III clinical study, and other product candidates in various stages of clinical development and preclinical development. On March 14, 2007, NPS Pharmaceuticals, Inc. announced that it was restructuring the Company.
